Project Grant R01NS138440
Award Date
5/15/25
Completion Date
4/30/30
Dollars Obligated
$443K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop mRNA-based gene therapies for treating pediatric high-grade gliomas, particularly diffuse midline glioma (DMG). The $142,452 award, effective from Sep 18, 2024 to Aug 31, 2026, aims to optimize the delivery of mRNA using lipid nanoparticles to...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $644,967.00 to the University of Pittsburgh to conduct research on the role of the SMARCD3/BAF60C protein in medulloblastoma, a type of brain cancer. The research aims to delineate how SMARCD3 regulation by the MYC-EZH2 pathway contributes to medulloblastoma formation and...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $574,427 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of Pittsburgh to investigate the role of amino acid metabolism in regulating the growth and immune interactions of glioblastoma, an aggressive form of brain cancer. The research aims to uncover the molecular and cellular mechanisms by which selective amino acid catabolism in glioblastoma...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 24-month, $430,375 Project Grant (CFDA 93.853) to Emory University to develop human organoid models for pediatric high-grade gliomas (PHGGs). The research aims to 1) create PHGG organoid models using human patient-derived cancer stem cells and 2) model how interactions between PHGG cells and the human neural microenvironment affect responses to tyrosine kinase inhibitors and other anti-tumor drugs. The goal is to...
This $717,802 federal Project Grant award was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to elucidate the cellular and molecular mechanisms underlying the development of high-grade gliomas with H3.3G34 mutations (HGG-G34). Key objectives include: 1) identifying the transcriptional targets of the DMRTA2 transcription...
This $460,940 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to investigate the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories. The research focuses on elucidating the epigenetic and transcriptional mechanisms by which two specific glioma-associated risk SNPs, rs7572263 and rs78378222, dysregulate...
This Project Grant award for $676,388.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The grant supports research at St. Jude Children's Research Hospital to explore how proteins involved in controlling neuronal migration and polarity also impact chromatin organization and neuronal differentiation during brain development. The research...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $190,485 to Indiana University Indianapolis to investigate the molecular mechanisms underlying differentiation failure in neuroepithelial stem cells with NF2 gene mutations. The goal is to identify the cellular hierarchy and dysregulated signaling pathways in these...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Regents of the University of California, San Francisco (UCSF) in the amount of $686,979 will support research aimed at understanding and disrupting metabolic mechanisms of immunosuppression in diffuse midline gliomas (DMGs), an aggressive form of childhood brain cancer. The key objectives are to: 1) delineate how the H3K27M mutation in DMGs upregulates the glycolytic enzyme PGK1 to...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $670,904 to The Regents of the University of California, San Francisco (UCSF) to develop new metabolic therapy and imaging approaches for treating diffuse midline gliomas (DMGs), a devastating type of brain cancer in children. The key products and services to be delivered include: Determining if combined inhibition of the enzymes G6PD and...